More information about the Hungarian coronavirus drug appeared in the program of InfoRádió. Immunologist Imre Kacskovics helps clear up who will receive the medicine.
Imre Kacskovics, the Dean of the Faculty of Science of Eötvös Loránd University, spoke to InfoRádió. He stated that clinical testing will begin in early 2023. Before that, they are performing animal experiments and toxicological tests, writes index.hu.
“We’ve been able to identify molecules that are new. They’re new in the sense that we think they’re patentable. And we’ve been able to detect these molecules and drugs in the summer to prevent the virus from infecting cells,” Kacskovics said.
Animal experiments are currently underway.
“We are very confident that these experiments will be successful and we will be able to select the molecule that we will take further through drug development.” With this, Kacskovics referred to what phases precede the clinical phase.
The toxicological tests show whether the medicine prevents infection. It is also important to note that the drug does not cause any other illness.
The toxicological phase lasts for one year.
The immunologist said the drug resembled the antibody. So, people can use the Hungarian medicine for prevention. In other words, if someone is not protected by vaccinations, this Hungarian drug can help. Kacskovics stressed that protection by the drug will soon develop. It works as early as after 6-10 hours. Drug protection may last 3-4 months.
The drug is only an additional defence to vaccination.
So, the immunologist recommends the medication with an existing vaccine. It is primarily for those with a weaker immune system. The preparation of the drug is complicated. For this reason, only Richter Gedeon’s biotechnology plant can produce this new Hungarian medicine, writes portfolio.hu. The drug will be available intravenously or in the form of a nasal spray.
Source: Inforádió, index, portfolio.hu